Literature DB >> 9300750

MR evaluation of radiation otomastoiditis.

R Nishimura1, Y Baba, R Murakami, T Baba, M Furusawa, T Ishikawa, Y Ushio, M Takahashi.   

Abstract

PURPOSE: The purpose of this study was to evaluate the incidence of radiation otomastoiditis, on using T2-weighted magnetic resonance (MR) imaging, in relation to radiation fields, doses, intervals, and clinical symptoms after radiotherapy that included the temporal bone in the fields. METHODS AND MATERIALS: We performed follow-up MR examinations at various intervals after radiotherapy including the temporal bones for 270 ears of 114 patients with various diseases of the head and neck and intracranial regions. The middle ear and mastoid air cells on T2-weighted images were scored as follows; showing no high signal intensity, a local high signal intensity area, or a high signal intensity area occupying the entire middle ear and all mastoid air cells. The radiation fields as depicted on the lateral simulator films classed as anterior to the clival line, posterior to the clival line, or both.
RESULTS: The incidence of radiation otomastoiditis depicted on T2-weighted MR images increased in the patients who had received irradiation doses of 50 Gy or more. In the patients with doses of less than 50 Gy, the incidence was 18% within 6 months following radiotherapy, 13% at between 6 and 12 months, and 8% after 12 months, whereas it was more than 50% at any period after radiotherapy in the patients with 50 Gy or more. The incidence of radiation otomastoiditis was quite high in the patients whose radiation fields included region both anterior and posterior to the clival line.
CONCLUSION: The incidence of radiation otomastoiditis as demonstrated on T2-weighted MR images is increased at irradiation doses of 50 Gy or more. To reduce the incidence of severe radiation otomastoiditis, the irradiation fields of the temporal bone when the dose is 50 Gy or more should be limited to as small as possible. The clival line is considered to be a good landmark in reducing the irradiation field when doses of 60-70 Gy are delivered in curative radiotherapy.

Entities:  

Mesh:

Year:  1997        PMID: 9300750     DOI: 10.1016/s0360-3016(97)00302-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  In favour of bladder preservation using combined modality treatment.

Authors:  Himu Lukka
Journal:  Can Urol Assoc J       Date:  2009-10       Impact factor: 1.862

2.  High incidence and spontaneous resolution of mastoid effusion after craniotomy on early postoperative magnetic resonance images.

Authors:  T Watanabe; N Saito; N Sato; A Takahashi; H Fujimaki; M Tosaka; T Sasaki
Journal:  Neuroradiology       Date:  2003-06-17       Impact factor: 2.804

3.  Comparison of MR imaging findings in paediatric and adult patients with acute mastoiditis and incidental intramastoid bright signal on T2-weighted images.

Authors:  R Saat; G Mahmood; A Laulajainen-Hongisto; L Lempinen; A A Aarnisalo; J Jero; A Markkola
Journal:  Eur Radiol       Date:  2015-11-25       Impact factor: 5.315

4.  Incidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma.

Authors:  Ji-Jin Yao; Guan-Qun Zhou; Xiao-Li Yu; Ling-Long Tang; Lei Chen; Yan-Ping Mao; Li Lin; Lu-Lu Zhang; Jian-Yong Shao; Ying Guo; Jun Ma; Ying Sun
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

5.  Predictors of Mastoiditis after Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma: A Dose-Volume Analysis.

Authors:  Ji-Jin Yao; Guan-Qun Zhou; Ya-Nan Jin; Wang-Jian Zhang; Li Lin; Xiao-Li Yu; Jian-Yong Shao; Jun Ma; Ying Sun
Journal:  J Cancer       Date:  2016-01-08       Impact factor: 4.207

6.  Dose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma.

Authors:  Ji-Jin Yao; Guan-Qun Zhou; Li Lin; Wang-Jian Zhang; Ying-Lin Peng; Lei Chen; Ling-Long Tang; Yan-Ping Mao; Jun Ma; Ying Sun
Journal:  Sci Rep       Date:  2015-09-01       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.